← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 1
AdV-tk (AdV-tk)
Candel Therapeutics, Inc.·Glioma, Malignant
ORR 11%
Overview
Program
AdV-tk
Overview
Company
Candel Therapeutics, Inc.
Overview
Modality
ANTIBODY
Overview
Target
Glioma, Malignant
Overview
Indication
Malignant Glioma; Recurrent Ependymoma
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
MoA
Biomarker
biomarkers were evaluated in tumor and blood before and after GMCI
PK/PD
Species
Mouse, Human
PK/PD
Animal (cat.)
Human, Mouse
PK/PD
Experiment
biodistribution
Toxicology
Species
Mouse, Human
Toxicology
Animal (cat.)
Human, Mouse
Toxicology
Major finding
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.. Gene-mediated cytotoxic immunotherapy (GMCI) is an immune strategy implemented through local delivery of an adenovirus-based vector expressing the thymidine kinase gene (aglatimagene besadenovec, AdV-tk) followed by anti-herpetic prodrug valacyclovir. A phase I dose escalation trial of…
Toxicology
CRS
grade 2
Clinical
ORR
11%
Clinical
PFS
0
Clinical
OS
15
Clinical
Result source
ClinicalTrials.gov NCT02831933
Clinical
Data Tier / Score
A · 34
Clinical
Program phase
PHASE_1
Clinical
Clinical sync
2026년 7월 18일 (8일 전)